eli lilly glp 1 direct markets single-dose Zepbound vials at a major price cut Lilly's GLP-1 Direct-To-Consumer Move Changes

Injecting through clothing or into areas with poor hygiene increases infection risk

Their use has now expanded beyond diabetes, as off-label prescriptions for obesity management and even cosmetic weight loss have become increasingly common

And the government needs to intervene, requiring Medicare to treat obesity as a chronic condition and initiating coverage for Part D enrollees who are prescribed a GIP or GLP-1 medication solely for the treatment of weight loss, rather than restricting coverage to those with diabetes or cardiovascular disease

doi: 10.2337/dc11-2113

Rybelsus is a daily tablet, and Ozempic is a weekly injection

Mojsov S, et al